193 completed, 41 recruiting, 39 terminated, 30 unknown. 358 Phase 1, 133 Phase 2.
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | AbelZeta Inc. | 119 | 2027-02-01 | 2026-10-13 |
| An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1 CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV) | Phase 1 / Phase 2 | Not yet recruiting | University Hospital Tuebingen | 36 | 2027-01-01 | 2026-11-12 |
| A Basket Study of CTA313 in Participants With Active Autoimmune Diseases CTA313 UCAR T Cell Infusion - Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS) | Phase 1 | Not yet recruiting | Imviva Bio | 81 | 2026-12-01 | 2026-08-24 |
| Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 20 | 2026-12-01 | 2026-10-16 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica | Phase 1 / Phase 2 | Not yet recruiting | CRISPR Therapeutics | 220 | 2026-11-01 | 2026-10-22 |
| A Phase 1/2a Study of Oral PRO-1562 in Healthy Subjects and Patients With Relapsing Multiple Sclerosis PRO-1562 Oral Capsules, Placebo Oral Capsule - Multiple Sclerosis | Phase 1 / Phase 2 | Recruiting | Progentos Therapeutics | 160 | 2026-10-01 | 2026-09-29 |
| A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus US-Ocrevus, PB018, EU-Ocrevus - Multiple Sclerosis | Phase 1 | Not yet recruiting | Polpharma Biologics International AG | 222 | 2026-10-01 | 2026-05-28 |
| Phase Ib/II Study of SYS6020 in Relapsing/Refractory Multiple Sclerosis SYS6020 injection - Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | Tongji Hospital | 25 | 2026-09-16 | 2026-08-10 |
| Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy Clemastine Fumarate, Placebo - Demyelinating Diseases, Demyelination; Corpus Callosum | Phase 1 / Phase 2 | Not yet recruiting | University of California, San Francisco | 44 | 2026-09-15 | 2026-03-11 |
| OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis glibenclamide, Placebo - Multiple Sclerosis, Neuropathic Pain | Phase 1 | Not yet recruiting | University of Maryland, Baltimore | 10 | 2026-09-01 | 2025-10-28 |
| An Exploratory Study of Obinutuzumab β in the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Obinutuzumab β - Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), Obinutuzumab β | Phase 1 / Phase 2 | Not yet recruiting | Zhongming Qiu | 24 | 2026-07-15 | 2026-07-10 |
| Intermittent Low Oxygen Breathing: A First Study Testing Different Disease Stages in People Living With MS Acute Intermittent Hypoxia - Multiple Sclerosis | Phase 1 / Phase 2 | Not yet recruiting | University of Saskatchewan | 9 | 2026-07-01 | 2026-06-05 |
| A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy CD20/BCMA-directed CAR-T cells Autologous 2nd generation - Multiple Sclerosis (MS), Myasthenia Gravis (MG) | Phase 1 | Not yet recruiting | The Affiliated Hospital of Qingdao University | 18 | 2026-07-01 | 2026-06-30 |
| IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis IDP-023, Ocrelizumab, Interleukin-2 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS) | Phase 1 | Suspended | Indapta Therapeutics, INC. | 34 | 2026-06-30 | 2025-04-30 |
| Transcranial Magnetic Stimulation for Depression in Multiple Sclerosis Repetitive Transcranial Magnetic Stimulation (rTMS) - Multiple Sclerosis, Depression - Major Depressive Disorder | Phase 1 | Not yet recruiting | University of Calgary | 20 | 2026-06-15 | 2026-05-01 |
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | 2026-06-01 | 2026-06-25 | |
| Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis S103 cells - Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis | Phase 1 | Recruiting | Xijing Hospital | 9 | 2026-05-08 | 2026-08-05 |
| Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment KITE-363, Fludarabine, Cyclophosphamide - Chronic Inflammatory Demyelinating Polyneuropathy, Myasthenia Gravis | Phase 1 | Recruiting | Kite, A Gilead Company | 57 | 2026-04-10 | 2026-10-19 |
| A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis. Universal STAR-T Cell Injection - Multiple Sclerosis (MS) | Phase 1 | Not yet recruiting | Daishi Tian | 24 | 2026-04-07 | 2026-04-13 |
| Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases. Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine - Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 | Recruiting | Tongji Hospital | 6 | 2026-04-01 | 2026-05-12 |
Showing 20 of 358. Sign in to see all of them.
Multiple Sclerosis (250) · Multiple Sclerosis, Relapsing-Remitting (59) · Multiple Sclerosis, Chronic Progressive (56) · Neuromyelitis Optica (32) · Autoimmune Diseases (21) · Leukodystrophy, Metachromatic (11) · Adrenoleukodystrophy (10) · Myasthenia Gravis (9) · Autoimmune Diseases of the Nervous System (8) · Guillain-Barre Syndrome (8) · Nervous System Diseases (8) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (8) · Alzheimer Disease (7) · Fatigue (7)
Nervous System Diseases (350) · Immune System Diseases (327) · Autoimmune Diseases of the Nervous System (320) · Demyelinating Autoimmune Diseases, CNS (313) · Autoimmune Diseases (307) · Pathological Conditions, Signs and Symptoms (109) · Pathologic Processes (92) · Disease Attributes (83) · Chronic Disease (75) · Central Nervous System Diseases (47) · Multiple Sclerosis (44) · Brain Diseases (40) · Eye Diseases (37) · Cranial Nerve Diseases (36)
Cyclophosphamide (8) · Interferon beta-1a (7) · Thioctic Acid (7) · fludarabine (7) · Methylprednisolone (6) · Dimethyl Fumarate (5) · Rituximab (5) · Methylprednisolone Hemisuccinate (4) · ocrelizumab (4) · Acyclovir (3) · Cholecalciferol (3) · Exercise (3) · Fatty Acids, Omega-3 (3) · Filgrastim (3) · N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline (3)
Biogen (14) · GlaxoSmithKline (11) · Johns Hopkins University (8) · National Institute of Neurological Disorders and Stroke (NINDS) (8) · Oregon Health and Science University (7) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Sanofi (5) · Brigham and Women's Hospital (4) · Contineum Therapeutics (4) · Hadassah Medical Organization (4) · Hoffmann-La Roche (4) · Novartis Vaccines (4) · Sheba Medical Center (4) · Shire (4) · Stanford University (4)
United States (168) · United Kingdom (31) · Australia (22) · China (22) · Germany (22) · Canada (18) · Spain (16) · Israel (13) · France (12) · Italy (11) · Switzerland (8) · Russia (7) · Belgium (6) · Denmark (6) · Poland (6)
Bibiana Bielekova, M.D. (5) · Stephen Huhn, MD (5) · Daniel S Reich, M.D. (4) · Albert Lo, MD PhD (3) · Joanne Kurtzberg, MD (3) · Michael Levy, MD, PhD (3) · Tarun Singhal, MD (3) · Vijayshree Yadav, MD (3) · Anat Achiron, MD PhD (2)
PMID 31072380, PMID 12542793, PMID 15864738, PMID 20937945, PMID 23982748, PMID 24759263, PMID 25442786, PMID 27423899, PMID 27574516, PMID 31501122, PMID 33332761, PMID 36196048, PMID 39251561, PMID 11160464, PMID 11231629, PMID 11399225, PMID 11955556, PMID 12700753, PMID 14615106, PMID 16015332, PMID 17058754, PMID 17502467, PMID 17548546, PMID 17698695, PMID 17875557, PMID 18507817, PMID 18565456, PMID 18671877, PMID 18794494, PMID 19798728, PMID 19833477, PMID 19847907, PMID 19892975, PMID 20404843, PMID 20445531, PMID 21372112, PMID 21570386, PMID 21697250, PMID 21978993, PMID 22056644, PMID 22236384, PMID 22837038, PMID 23200102, PMID 23272061, PMID 23595275, PMID 23618062, PMID 23623397, PMID 23669008, PMID 23733308, PMID 23740901
2015 (5), 2018 (4), 2014 (2), 2016 (2), 2023 (2), 2008 (1), 2017 (1), 2019 (1), K23AT002155 (1), K23AT004433 (1), K23NS087151 (1), P41EB022544 (1), P50AT000066 (1), R01AG076153 (1), R01AG085561 (1)